ClinicalTrials.gg
CompletedNCT05288075FORELLIUpdated Jul 13, 2022

Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product

A Phase 1 interventional study of Indacaterol/glycopyrronium in Healthy Volunteers, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a formulation feasibility study to to compare relative bioavailability of indacaterol and glycopyrronium after administration of single doses of 3 Easyhaler test products and Ultibro Breezhaler. The study treatments will be administered with concomitant oral charcoal to block absorption via gastrointestinal tract and to assess pulmonary absorption only.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. Healthy males and females
  2. 18-60 years of age
  3. 19-30 kg/m2
  4. Weight at least 50 kg
  5. Written obtained

Main Exclusion Criteria:

  1. Evidence of a cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic, endocrine, neurological or psychiatric disease
  2. Any condition requiring regular concomitant treatment
  3. Any clinically significant abnormal laboratory value, vital sign or physical finding that in the opinion of the investigator could interfere with the interpretation of study results or cause a health risk for the subject
  4. Known to indacaterol or glycopyrronium
  5. Pregnant or lactating females and females of not using of acceptable effectiveness
  6. Blood donation or loss of significant amount of blood within 90 days prior to the first study treatment administration
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant A

    Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant A in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).

    Drug: Indacaterol/glycopyrronium

  • Experimental
    Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant B

    Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant B in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).

    Drug: Indacaterol/glycopyrronium

  • Experimental
    Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant C

    Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant C in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).

    Drug: Indacaterol/glycopyrronium

  • Active comparator
    Ultibro® Breezhaler® 85/43 µg inhalation powder, hard capsule

    Each subject will receive 2 capsules of Ultibro® Breezhaler® (=Indacaterol/glycopyrronium) as a single dose in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).

    Drug: Indacaterol/glycopyrronium

Interventions

  • DrugIndacaterol/glycopyrronium

    Drug pages: IndacaterolStudies of IndacaterolIndacaterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GlycopyrrolateStudies of GlycopyrrolateGlycopyrrolate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler. In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.

    Also known as: Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant A with charcoal, Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant B with charcoal, Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant C with charcoal, Ultibro® Breezhaler® 85/43 µg inhalation powder, hard capsule with charcoal

06

What researchers measure

Primary outcomes

  1. Peak indacaterol and glycopyrronium concentration in plasma (Cmax)

    Pharmacokinetic parameters of indacaterol and glycopyrronium

    Time frame: between 0-72 hours after dosing

  2. Area under the concentration-time curve from time zero to 72 hours (AUC72)

    Pharmacokinetic parameters of indacaterol and glycopyrronium

    Time frame: between 0-72 hours after dosing

Secondary outcomes

  1. Time to reach peak indacaterol and glycopyrronium concentration in plasma (tmax)

    Pharmacokinetic parameters of indacaterol and glycopyrronium

    Time frame: between 0-72 hours after dosing

  2. Area under the concentration-time curve from time zero to 30 minutes (AUC30)

    Pharmacokinetic parameters of indacaterol and glycopyrronium

    Time frame: between 0-30 minutes after dosing

Other outcomes

  1. Adverse events

    Adverse events

    Time frame: Up to 11 weeks

07

Study locations

1 site
  • CRST Helsinki Oy
    Helsinki, Finland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jun 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Mar 18, 2022
StartActual
Feb 28, 2022
Primary completionActual
Jun 27, 2022
CompletionActual
Jun 27, 2022
Last update
Jul 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05288075
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Feb 28, 2022
Primary completion
Jun 27, 2022
Completion
Jun 27, 2022
Last update
Jul 13, 2022

Study contacts

Orion Corporation Clinical Study Director
study director · Orion Corporation, Orion Pharma
Clinical Study Director
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Indacaterol · Glycopyrrolate

Start the discussion